FDA grants fast track status to fruquintinib for metastatic colorectal cancer

The FDA granted fast track designation to fruquintinib for treatment of certain patients with metastatic colorectal cancer.The designation applies to use of the agent for patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy and — if RAS wild-type — an anti-EGFR therapy.Fruquintinib (Elunate; Hutchison China MediTech Limited, Eli Lilly) is a selective oral inhibitor of VEGFR 1/2/3.The phase 3 FRESCO study showed fruquintinib improved OS among patients in China with metastatic colorectal cancer, leadingRead More

Share on facebook
Share on twitter
Share on linkedin